Clinical trials: Bladder Tumors
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Urinary Bladder Neoplasms
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
The purpose of this study is to evaluate the safety and efficacy of applying cryoablation as an adjuvant therapy with TUR to treat bladder tumor.
- Trial name
- NCT02760953
- Testing
- Cryoablation, Epirubicin
- Volunteers
- 150 people
- Sponsor
- Huashan Hospital
Uterine Neoplasms, Cervix Neoplasms
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI)…
- Conditions
- Uterine Neoplasms, Cervix Neoplasms, Bladder Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00188695
- Testing
- MRI contrast agent Combidex (ferumoxtran-10)
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- University Health Network, Toronto
Carcinoma of Urinary Bladder, Superficial
Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC
In the proposed study the investigators aim to evaluate the effect of the standard of care dose (40mg) of MMC mixed with TC-3 gel (with sustained release mechanism on the drug) on low risk recurrent NMIBC lesions and to compare…
- Trial name
- OPTIMA (NCT01803295)
- Testing
- 40 mg MMC gel, Standard of care MMC mixed with water, 80 mg MMC gel
- Where
- 13 sites in Israel, Italy and 2 more
- Volunteers
- 80 people
- Sponsor
- UroGen Pharma Ltd.
Recurrent Bladder Cancer
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
This is an open-label, expanded access protocol to continue administration of bemarituzumab (FPA144) in a single patient with recurrent bladder cancer
- Trial name
- FPA144 (NCT03801278)
- Testing
- FPA144
- Sponsor
- Five Prime Therapeutics, Inc.
Rectal Cancer
The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study
Radiotherapy has a significant impact on local control, disease free survival and overall survival in patients with rectal cancer T2, N1, M0 and T3-4, any N, M0.
- Trial name
- NCT01142713
- Testing
- Patient Position During Radiotherapy
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Bladder Tumor
Microscopic-spectroscopic Examination for Urothelial Tissue Characterization
To evaluate the possibility to properly discriminate between healthy bladder tissue and BCa with a multimodal fiber optic spectroscopy (MFOS) technique, in order to possibly introduce a more objective way to detect BCa, thus…
- Trial name
- MSUT (NCT04310813)
- Testing
- Multimodal spectroscopic analysis
- Volunteers
- 114 people
- Sponsor
- Careggi Hospital
Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
Bladder cancer is the most common malignancy of the urinary tract, and approximately 75% of cases are non-muscle invasive (NMIBC) at diagnosis. The standard treatment is transurethral resection of the bladder tumor (TURBT).
- Trial name
- RETRIEVE-BT (NCT07762820)
- Testing
- CURTIS retrieval device
- Where
- 9 sites in Denmark, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Muscle Invasive Bladder Carcinoma
FL- 101 Study in Non-Metastatic MIBC
A pilot window of opportunity study of FL-101 in patients with non-metastatic MIBC who are eligible for radical cystectomy (RC) but are ineligible for, or decline, cisplatin-based neoadjuvant therapy.
- Trial name
- NCT05395260
- Testing
- FL-101
- Sponsor
- Flame Biosciences
Bladder Cancer
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
This trial is a randomized, multi-center, non-inferiority study comparing observation versus immediate surgery for low grade, noninvasive bladder cancer.
- Trial name
- NCT02700724
- Testing
- Immediate Surgery, Observation, Surveillance Cystoscopy and Urinary Cytology
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt University Medical Center
Advanced Solid Tumor, Colorectal Cancer
A Study of KF-0210 in Advanced Solid Tumors Patients
The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Colorectal Cancer, Lung Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT04713891
- Testing
- KF-0210 tablets, 120 mg, KF-0210 tablets, 240 mg, KF-0210 tablets, 450 mg
- Where
- Australia
- Volunteers
- 14 people
- Sponsor
- Keythera Pharmaceuticals (Australia) Pty Ltd
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer
This research aims to explore the therapeutic effect of neoadjuvant chemotherapy in muscular invasive bladder cancer of T2-4aN0M0, and the survival effect of combined-modality treatment model，then to clarify the probability of…
- Trial name
- NCT02861196
- Testing
- Intensity modulated radiation therapy, Radical cystectomy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Bladder Cancer
Investigator Grant (IG) 2022 27746
Background: Muscle-invasive bladder cancer (MIBC) is a systemic disease as >40% of patients (pts) ultimately develop recurrence after radical cystectomy (RC).
- Trial name
- NCT06341478
- Testing
- various neoadjuvant therapies
- Where
- Italy
- Volunteers
- 153 people
- Sponsor
- IRCCS San Raffaele
Oncology, Bladder Cancer
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high…
- Conditions
- Oncology, Bladder Cancer, Superficial Bladder Cancer, Recurrence
- Trial name
- NCT03121768
- Where
- Egypt
- Volunteers
- 761 people
- Sponsor
- Mansoura University
Bladder Cancer
MK-3475/BCG in High Risk Superficial Bladder Cancer
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet…
- Trial name
- MARC (NCT02324582)
- Testing
- Intravenous MK-3475/ Intravesical BCG
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Southern Illinois University
Bladder Cancer, Urothelial Carcinoma
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06040762
- Testing
- Best Practice, Exercise Intervention, App-Based Intervention
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Washington
Bladder Cancer
Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors
This clinical study is designed to evaluate the diagnostic performance of VisioCyt test, which would improve the early diagnosis of bladder cancer in order to optimize the management of individual patients as part of a cancer…
- Trial name
- VISIOCYT 1 (NCT02966691)
- Testing
- VisioCyt® diagnostic test
- Where
- 14 sites in France
- Volunteers
- 1,360 people
- Sponsor
- Vitadx
Bladder Cancer
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
This is an open-label, window of opportunity platform study for subjects with muscle-invasive bladder cancer (MIBC) who are deemed ineligible or refuse cisplatin-based neoadjuvant chemotherapy and are scheduled to undergo…
- Trial name
- NCT03978624
- Testing
- Pembrolizumab, Entinostat, Procedure/Surgery
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle-invasive Transitional Cell Carcinoma of the Bladder
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
The purpose of this study is to investigate the safety and efficacy of intratumoral REOLYSIN® therapy alone and in combination with standard neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
- Trial name
- NCT02723838
- Testing
- REOLYSIN®, Gemcitabine, Cisplatin
- Sponsor
- Oncolytics Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.